Share This Page
Drug Price Trends for CIPROFLOXACIN-HYDROCORT
✉ Email this page to a colleague
Average Pharmacy Cost for CIPROFLOXACIN-HYDROCORT
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CIPROFLOXACIN-HYDROCORT 0.2-1% | 00713-0851-09 | 29.09992 | ML | 2026-04-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
CIPROFLOXACIN-HYDROCORT Market Analysis and Financial Projection
Ciprofloxacin-Hydrocort: Market Analysis and Price Projections
What is CIPROFLOXACIN-HYDROCORT commercially?
“Ciprofloxacin-hydrocort” is a fixed-dose combination of:
- Ciprofloxacin (antibiotic)
- Hydrocortisone (topical corticosteroid)
In practice, the combination is marketed mainly as otic/ophthalmic drops (ear/eye), depending on local labeling. Pricing and market sizing vary materially by region, dosage form, pack size, and whether it is brand or generic.
Where does pricing concentrate by geography?
Ciprofloxacin is widely generic, and hydrocortisone is off-patent; pricing therefore clusters around:
- Generic competition intensity
- Regulatory reimbursement regimes
- Retail pharmacy contracting and wholesale margins
- Switching behavior after loss of exclusivity for branded products
As a result, forecast pricing is dominated by generic price erosion and channel mix, not by innovation-driven premiumization.
Current Market Structure
How is the market split between branded and generic?
The combination is typically sold as genericized products in many markets because:
- Ciprofloxacin has long-standing generic availability globally.
- Hydrocortisone products are broadly generics.
- Fixed-dose combinations generally lose competitive pricing power quickly after generic entry.
Implication for price forecasting: the base case should model continued downward price pressure with intermittent stabilization when particular SKUs face fewer competitors.
Pricing Benchmarks (What typically drives the unit price?)
Which product attributes set price per ml?
Unit economics for ciprofloxacin-hydrocort products typically hinge on:
- Concentration and formulation (for example, ciprofloxacin strength and hydrocortisone dose per ml)
- Bottle size (5 ml, 10 ml, 15 ml are common pack bands in many jurisdictions)
- Sterility/packaging requirements (especially for ophthalmic)
- Branding status (originator or “authorized generic” versus standalone generic)
- Tender and pharmacy reimbursement rules
Because fixed-dose combinations can be sold with different label strengths and pack formats across countries, an actionable projection must be anchored to specific SKU bands rather than the molecule name alone.
Price Projection Model (Generic Erosion Framework)
What is the most likely price trajectory?
For ciprofloxacin-hydrocort, the expected trajectory across mature markets follows a generic life-cycle pattern:
- Near-term (0 to 12 months): modest price drops or flat pricing if the SKU already competes with multiple generics and channel substitution is complete.
- Mid-term (12 to 36 months): renewed erosion if additional generic entries occur or if tenders reset contracted prices.
- Long-term (36 to 60 months): price tends to flatten at a lower floor defined by manufacturing cost structure, logistics, and regulatory margin caps (where they apply).
Directionally, unit price declines dominate because the competitive basis is cost plus regulatory compliance, not differentiated clinical performance.
Regional Price Outlook (Direction, timing, magnitude bands)
How does forecast vary by market maturity?
| Region archetype | Competitive depth | Expected 12-month change | Expected 24-month change | Expected 36 to 60-month change |
|---|---|---|---|---|
| Highly mature (multiple generics, stable reimbursement) | High | 0% to -8% | -3% to -15% | -0% to -10% (flattening) |
| Mid-maturity (generic entry still active in some channels) | Medium | -5% to -15% | -10% to -25% | -5% to -18% |
| Less mature / tender-led price resets | Lower | -8% to -20% | -15% to -30% | -10% to -22% |
Rationale: generic erosion accelerates when a tender or reimbursement schedule introduces additional SKUs or forces contract renegotiation.
Unit Economics and Demand Sensitivity
How do price changes affect volume?
For antibiotic-steroid eye/ear drops, demand is mostly driven by:
- Injury/infection incidence
- Prescriber preference and protocol behavior
- Availability at point of care
- Reimbursement coverage
In mature markets, price elasticity is typically low-to-moderate because prescriptions do not behave like OTC consumer products. Still, during tender cycles, volume can shift materially toward the lowest contracted SKU, making near-term erosion more pronounced.
Practical consequence: even when demand holds, unit price can still decline quickly in tender-heavy channels.
Competitive and Substitution Signals
What events typically move prices?
Price resets usually come from:
- New generic launches for the fixed combination (not just ciprofloxacin alone)
- Tender rebids by hospital groups
- Reimbursement list changes (inclusion/exclusion or reference pricing)
- Packaging or concentration changes that break old tender comparisons
Because fixed-dose combinations are SKU-specific, “molecule-level” generic entry does not automatically translate into price drops unless the exact combination strength and pack format are competitively tendered.
Financial Planning Ranges (SKU-level projection bands)
What price range should planning assume per unit?
Without a specified country, strength, and bottle size, precise pricing is not producible. What can be modeled is an erosion band that can be applied to your current baseline wholesale acquisition cost (WAC) for each SKU.
Use the following planning deltas from your current contracted or list price:
- 0 to 12 months: -0% to -12%
- 12 to 24 months: -5% to -22%
- 24 to 36 months: -5% to -18%
- 36 to 60 months: -0% to -12% (stabilization in many markets)
These bands assume continued generic availability and no brand-like differentiation.
Investment and R&D Implications
What does this mean for pipeline strategy?
For ciprofloxacin-hydrocort, innovation that does not change exclusivity status (or that does not create meaningful differentiation across regulatory and reimbursement criteria) usually cannot sustain premium pricing in mature markets. Value capture depends on:
- Securing exclusivity (new indication, new dosage form, reformulation with patentable benefit, or regulatory exclusivity regimes)
- Controlling channel access (tender positioning, formulary inclusion)
- Reducing total system cost through pack and dosing convenience (if permitted)
Key Takeaways
- Ciprofloxacin-hydrocort pricing is governed by generic erosion mechanics, not by innovation premium.
- Forecasting should use SKU-level anchoring (country, strength, bottle size, ophthalmic vs otic), then apply erosion deltas.
- Planning ranges for a typical mature generic market: -0% to -12% in 12 months, -5% to -22% in 24 months, then flattening by 36 to 60 months.
- Price resets concentrate around tender cycles, reimbursement list changes, and new fixed-combination generic entries.
FAQs
1) Is CIPROFLOXACIN-HYDROCORT likely to be brand-priced or generic-priced?
Generic-priced. The combination typically competes in a market with widespread availability of ciprofloxacin and hydrocortisone components, leading to rapid cost-based competition.
2) What drives the fastest price declines?
Tender-led contract rebids and reimbursement reference changes that re-rank the lowest-cost SKU for the same strength and pack.
3) Does ciprofloxacin generic entry alone reduce ciprofloxacin-hydrocort prices?
Not automatically. Prices fall most when the exact fixed-dose combination SKU enters competitively (same strength, formulation, and pack).
4) How should forecasts be modeled for a contracting hospital group?
Use a higher near-term erosion band tied to bid cycles (often within 0 to 12 months) and assume volume shifts to the lowest contracted SKU.
5) What is the realistic long-term price outlook?
Downward movement slows and tends to flatten when competitive entries saturate and pricing approaches a cost-plus floor.
References
[1] FDA Orange Book. Drugs@FDA / Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
[2] EMA. European Medicines Agency: Find medicine (ciprofloxacin; hydrocortisone; combinations where applicable). European Medicines Agency. https://www.ema.europa.eu/en/medicines
[3] World Health Organization. WHO Model Formulary and related guidance on antibiotics and topical corticosteroid use in ocular/otic indications. World Health Organization. https://www.who.int/
[4] IBM Micromedex. Drug pricing and formulary references (where available by jurisdiction). IBM. https://www.micromedexsolutions.com/
More… ↓
